Synlogic已经选择Science 37为其正在进行的治疗苯丙酮尿症的研究药物拉巴芬-3(以前称为SYNB1934)的关键3期试验Synheny-3提供虚拟临床试验技术和服务

2023-07-11 20:02

The Synpheny-3 trial aims to study the effectiveness of labafenogene marselecobac, an orally administered, investigational medicine based on a genetically engineered probiotic, in PKU patients.
Synlogic anticipates enrolling approximately 150 patients who have the potential to receive the investigational drug and to be monitored for up to three years.
The Science 37 Metasite will expand access to the trial for patients who may be unable or prefer not to travel to research sites for study visits. Science 37 will also provide its unified platform to the study's physical research sites, ensuring end-to-end data quality and consistency, no matter where or how data is captured.